Business
Signage for an Hermes store in Amsterdam
Signage for an Hermès store in Amsterdam (Getty Images)

Hermès posted record revenues, despite Walmart’s viral Birkin dupe

A lot of people are still workin’ for a Birkin, even as look-alike products threaten the brand.

Birkin bag maker Hermès reported better-than-expected sales for 2024 on Friday, with revenues reaching €3.96 billion ($4.15 billion) in Q4 — up 18% year over year. Hermès rose modestly on the news, as the French brand bucked the slowdown recently observed in the luxury sector.

Total revenues topped €15 billion (~$15.7 billion) in 2024, boosted by a strong performance in the Americas and significant growth in its leather goods category (up 16%). Despite the pressure of looming US tariffs, analysts remained confident that Hermès could bypass the impact of import duties by bumping prices further, since demand for its ~$270 ties, ~$12,000 bags, and ~$1,050 belts exceeds its supply.

Wirkin hard, or hardly Birkin
Sherwood News

Wirkin hard, or hardly Birkin

Hermès is the world’s oldest luxury brand, with artisanal roots dating back to 1837. The fashion house launched its iconic Birkin bag over a century later, which has since been cemented as a status symbol — not only through appearances in rap lyrics and Kardashian closets, but through the difficulty of acquiring one.

While Hermès no longer keeps a waiting list for wannabe bag holders, buyers must still demonstrate commitment to the brand with a history of purchases. Even then, by Sotheby’s estimates, prices continue to rise, with the cost of a Birkin 25 bag up 20% in the last three years alone.

This exclusivity has been controversial; however, the launch of a viral Walmart dupe (dubbed “Wirkins”) last December for just $78 gave consumers the opportunity to buy a substitute at less than 1% the price of an actual Birkin bag. Hermès CEO Axel Dumas addressed the look-alike on the earnings call: “It’s difficult to know what, exactly, to think about it apart from the fact that it irritated me — annoyed me.”

But, so far, Walmart’s alternative is doing little to deter the world’s wealthiest clientele from a bag that requires previous splurging in order to be splurged on.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.